Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura

Article Sidebar

PDF HTML
Submitted: February 9, 2018
Published: Feb 16, 2018
DOI: 10.29328/journal.jcn.1001010

Main Article Content

Sabaa Asif*
Resident Trainee in Nephrology Department at Ziauddin Hospital, Karachi, Pakistan
Sumbal Nasir Mahmood
Professor and Head of Nephrology Department at Ziauddin Hospital, Karachi, Pakistan
Osama Kunwer Naveed
Medical Student at Dow Medical College, Karachi, Pakistan

Article Details

Asif, S., Mahmood, S. N., & Naveed, O. K. (2018). Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura. Journal of Clinical Nephrology, 2(1), 001–004. https://doi.org/10.29328/journal.jcn.1001010
Case Reports

Copyright (c) 2018 Asif S, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Mondal S, Goswami RP, Sinha D, Basu K, Das S, et al. Posterior reversible encephalopathy syndrome in a patient with lupus nephritis on rituximab therapy: a challenge to find the offender. Lupus. 2015; 25: 445-446. Ref.: https://goo.gl/AWWGxH

Legriel S, Pico F, Azoulay E. Understanding Posterior Reversible Encephalopathy Syndrome. Annual Update in Intensive Care and Emergency Medicine. 2011; 1: 631-653. Ref.: https://goo.gl/JeGsDz

Siddiqi A. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. Australas Med J. 2011; 4: 513-515. Ref.: https://goo.gl/B3ZA8x

Mehta Y, Ramachandran K, Gundre P, Kupfer Y, Tessler S. Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura. Chest. 2009; 136. Ref.: https://goo.gl/dLdrAA

Harirchian M, Ghaffarpour M, Tabaeizadeh M, Siroos B. Immunosuppressive Drugs, an Emerging Cause of Posterior Reversible Encephalopathy Syndrome: Case Series. J Stroke Cerebrovasc Dis. 2015; 24:191-195. Ref.: https://goo.gl/Y2YLRj

Mavragani CP, Vlachoyiannopoulos PG, Kosmas N, Boletis I, Tzioufas AG, et al. A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion. Rheumatology. 2004; 43: 1450-1451. Ref.: https://goo.gl/zqEeZX

Vargas A, Zeidman LA. Posterior Reversible Encephalopathy Syndrome with Rituximab in Hodgkin’s Lymphoma and Idiopathic Thrombocytopenic Purpura. J Neurol Transl Neurosci. 2013; 1: 1023. Ref.: https://goo.gl/driFv1

Bhat S, Rahman S. Rituximab Treatment in New and Refractory Thrombotic Thrombocytopenic Purpura (TTP) Patients: A Review. Int J Med Res Prof. 2016; 2: 1-6. Ref.: https://goo.gl/B9NbpY

Scully M. Rituximab in the treatment of TTP. Hematology. 2012; 17: 22-24. Ref.: https://goo.gl/pQrHQa

Habli M, Elyoussef N, Khoury M, Joubran Fares N. Rituximab-related posterior reversible encephalopathy syndrome in HUS patient post kidney transplant. Int J Case Rep Images. 2016; 7: 135-139. Ref.: https://goo.gl/b26waz